TIMOLOL Drug Patent Profile

Which patents cover Timolol, and when can generic versions of Timolol launch?

Timolol is a drug marketed by Epic Pharma Llc, Somerset, Alembic, Amneal, Dr Reddys, Eugia Pharma, Gland, Sandoz, Somerset Theraps Llc, Abbvie, Apotex, Apotex Inc, Bausch And Lomb, Caplin, Fdc Ltd, Fougera, Hikma, Ingenus Pharms Llc, J Molner, Mankind Pharma, Micro Labs, Pharmobedient, Sentiss Pharma, Ani Pharms, Chartwell Rx, Mylan, Quantum Pharmics, Rising, Teva, Usl Pharma, and Watson Labs. and is included in fifty-six NDAs.

The generic ingredient in TIMOLOL is timolol maleate. There are two drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the timolol maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Timolol

A generic version of TIMOLOL was approved as timolol maleate by MYLAN on June 8^th, 1990.

Summary for TIMOLOL

US Patents:	0
Applicants:	31
NDAs:	56
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	30
Clinical Trials:	256
Drug Prices:	Drug price information for TIMOLOL
Drug Sales Revenues:	Drug sales revenues for TIMOLOL
DailyMed Link:	TIMOLOL at DailyMed

See drug prices for TIMOLOL

See drug sales revenues for TIMOLOL

Recent Clinical Trials for TIMOLOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
SpyGlass Pharma, Inc.	PHASE3
Bausch & Lomb Incorporated	PHASE2
Glaukos Corporation	PHASE2

See all TIMOLOL clinical trials

Pharmacology for TIMOLOL

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

Medical Subject Heading (MeSH) Categories for TIMOLOL

Adrenergic beta-Antagonists

Anti-Arrhythmia Agents

Antihypertensive Agents

Anatomical Therapeutic Chemical (ATC) Classes for TIMOLOL

C07AA	Beta blocking agents, non-selective
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

S01ED	Beta blocking agents
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for TIMOLOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	TIMOLOL MALEATE	timolol maleate	TABLET;ORAL	072270-001	Apr 11, 1989		DISCN	No	No
Micro Labs	TIMOLOL MALEATE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	216596-001	Sep 7, 2022	AT3	RX	No	No
Fougera	TIMOLOL MALEATE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	074668-001	Mar 25, 1997		DISCN	No	No
Somerset Theraps Llc	TIMOLOL MALEATE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	216653-001	Jul 3, 2024	AT2	RX	No	No

Timolol Market Dynamics, Patent Expiration, Generic Competition, and Financial Trajectory

Last updated: October 22, 2026

Timolol is a mature, multisource beta-adrenergic blocker used primarily in ophthalmic products for glaucoma and ocular hypertension. Its core composition and use patents expired decades ago. Current commercial value comes from recurring prescription demand, established generic supply, branded combination products, gel-forming formulations, and manufacturing reliability rather than exclusivity.

The market is low-growth and price-sensitive. Prostaglandin analogs such as latanoprost have displaced timolol as common first-line therapy, but timolol remains relevant in combination regimens, patients who cannot tolerate prostaglandins, and lower-cost treatment settings. No biosimilar pathway applies because timolol is a synthetic small-molecule drug.

What is timolol and which products contain it?

Timolol is a nonselective beta-adrenergic receptor antagonist. Ophthalmic timolol lowers intraocular pressure by reducing aqueous humor production. Oral timolol products were historically used for cardiovascular indications, but ophthalmic use is the main continuing pharmaceutical market.

Product category	Active ingredient	Main indications	Commercial status
Timolol maleate ophthalmic solution	Timolol maleate	Glaucoma and ocular hypertension	Generic and branded
Timolol ophthalmic gel-forming solution	Timolol maleate	Glaucoma and ocular hypertension	Generic and branded or legacy branded
Timolol hemihydrate ophthalmic solution	Timolol hemihydrate	Glaucoma and ocular hypertension	Generic
Dorzolamide/timolol	Dorzolamide hydrochloride plus timolol maleate	Glaucoma and ocular hypertension	Generic and branded
Brimonidine/timolol	Brimonidine tartrate plus timolol maleate	Glaucoma and ocular hypertension	Generic and branded
Bimatoprost/timolol	Bimatoprost plus timolol	Glaucoma and ocular hypertension	Combination product, with separate patent history
Oral timolol	Timolol maleate	Cardiovascular indications	Limited modern commercial importance

The major branded reference product was Timoptic, developed by Merck. Cosopt combined timolol with dorzolamide, while Combigan combined timolol with brimonidine. These combination products have separate regulatory and patent histories from single-ingredient timolol.

How large is the timolol market?

There is no reliable standalone public revenue figure for global timolol sales because the molecule is sold through many generic manufacturers and is often reported within broader ophthalmic or glaucoma categories. Prescription claims data, tender volumes, and manufacturer revenue are more useful than branded sales figures.

The commercial market has four defining characteristics:

1. High generic penetration.
2. Low unit prices for standard ophthalmic solutions.
3. Stable demand from chronic glaucoma treatment.
4. Fragmented supply across regional manufacturers and contract producers.

Timolol is financially significant as a portfolio product rather than as a major standalone revenue driver. For generic companies, the product can provide predictable volume, but margins depend on manufacturing scale, procurement contracts, bottle availability, preservative systems, and regulatory compliance.

What drives timolol demand?

Demand is supported by several factors:

• Aging populations and higher glaucoma diagnosis rates.
• Chronic treatment duration.
• Use in combination therapy.
• Availability in public-health and low-cost formularies.
• Physician familiarity and broad regulatory history.
• Use where prostaglandin analogs are unavailable, poorly tolerated, or too expensive.

Demand is constrained by:

• Clinical preference for prostaglandin analogs.
• Ocular surface toxicity associated with preservatives such as benzalkonium chloride.
• Systemic beta-blocker effects, including bradycardia, hypotension, bronchospasm, and masking of hypoglycemia.
• Lower adherence compared with once-daily prostaglandin treatments in some patients.
• Generic price erosion.

The American Academy of Ophthalmology identifies topical beta blockers as an established glaucoma treatment class, but prostaglandin analogs are widely used because of efficacy, dosing convenience, and systemic safety considerations [1].

When did timolol lose market exclusivity?

Timolol lost meaningful composition-of-matter and primary product exclusivity decades ago. The original timolol patent estate is historical, not a current barrier to generic entry.

Merck introduced Timoptic in the late 1970s after FDA approval of ophthalmic timolol maleate. The original patent and early formulation protection expired long before the current generic market matured. Timolol now has no effective small-molecule exclusivity protection comparable to a new chemical entity.

Exclusivity category	Current position
Original active-ingredient patent	Expired
Original ophthalmic product patents	Expired
New chemical entity exclusivity	Expired
Pediatric exclusivity	No current commercial significance
Orphan-drug exclusivity	Not applicable to the core product
Regulatory exclusivity for generic versions	None of material commercial duration
Biosimilar exclusivity	Not applicable

The exact commercial end date depends on the specific dosage form, combination, and jurisdiction. Single-ingredient timolol has been open to generic competition for many years.

What patents protect timolol today?

No unexpired patent appears to protect the core timolol molecule or conventional timolol maleate ophthalmic solution in the United States. The relevant patent exposure is primarily historical or product-specific.

Core composition and use patents

The original U.S. patent family covering timolol and related beta-blocking compounds was filed in the 1960s and issued before the modern Hatch-Waxman framework. Those patents expired decades ago. Their expiration removed the primary barrier to generic development.

Historical patent activity covered:

• The timolol chemical structure.
• Beta-adrenergic blocking activity.
• Pharmaceutical salts, including timolol maleate.
• Ophthalmic formulations.
• Treatment of elevated intraocular pressure.

These rights no longer support exclusivity for the active ingredient.

Formulation patents

Formulation protection has been more commercially relevant than molecule protection. Potential formulation categories include:

• Gel-forming ophthalmic solutions.
• Preservative-free unit-dose products.
• Low-concentration formulations.
• Combination products.
• Bottle and delivery systems.
• Stabilized or buffered formulations.

Most older formulation patents associated with mainstream timolol products have expired. Later patents may have applied to specific combinations or delivery systems, but they do not recreate broad exclusivity for standard timolol solution.

A generic manufacturer can generally compete with conventional timolol ophthalmic products if it satisfies FDA requirements for pharmaceutical equivalence, bioequivalence where applicable, sterility, container closure, stability, and manufacturing quality.

What is the Orange Book status of timolol?

Timolol has no current Orange Book structure capable of supporting broad blocking exclusivity for the active ingredient. The Orange Book lists FDA-approved drug products and, where applicable, patent and exclusivity information. Listings can vary by product, dosage form, sponsor, and update date [2].

The practical distinction is between:

• Single-ingredient timolol products.
• Timolol-containing combinations.
• Gel-forming products.
• Products with device or delivery claims.

A patent listed against a combination product does not necessarily block an ANDA for plain timolol maleate ophthalmic solution. Conversely, a generic applicant for a combination product may face different listed patents from an applicant for single-agent timolol.

Which companies compete in the timolol market?

Competition is fragmented. The market includes large generic companies, ophthalmic specialists, regional manufacturers, and contract manufacturing organizations.

Companies historically associated with timolol or timolol-containing products include:

• Merck, through Timoptic and related legacy products.
• Sandoz and Novartis-associated generic operations.
• Teva Pharmaceutical Industries.
• Bausch + Lomb.
• Akorn, before its bankruptcy and asset restructuring.
• Hikma Pharmaceuticals.
• Apotex.
• Lupin.
• Viatris and legacy Mylan operations.
• Sun Pharmaceutical Industries.
• Cipla.
• Dr. Reddy's Laboratories.
• Regional manufacturers in Europe, Asia, Latin America, and emerging markets.

The competitive field changes by country because ophthalmic products require local registrations, approved manufacturing sites, tender access, and reliable sterile production. A company may have regulatory approval without holding meaningful market share.

How does timolol compare with competing glaucoma drugs?

Timolol competes mainly with prostaglandin analogs, alpha-2 agonists, carbonic anhydrase inhibitors, and fixed-dose combinations.

Drug class	Examples	Relative commercial position
Prostaglandin analogs	Latanoprost, bimatoprost, travoprost	Strong first-line position; once-daily dosing
Beta blockers	Timolol, betaxolol	Mature, low-cost, often adjunctive
Carbonic anhydrase inhibitors	Dorzolamide, brinzolamide	Used alone or in combinations
Alpha-2 agonists	Brimonidine	Common adjunctive therapy
Rho kinase inhibitors	Netarsudil	Newer, branded or recently commercializing category
Fixed combinations	Dorzolamide/timolol, brimonidine/timolol	Important for adherence and additional pressure reduction

Timolol retains a cost advantage over many branded or newer therapies. Its clinical disadvantages include systemic beta-blockade and twice-daily dosing for many products. Prostaglandins generally have stronger commercial positioning in markets where patients and payers can access them.

What generic entry risks exist for timolol?

The risk of new generic entry is high for standard timolol products because the molecule and core products are long off patent. The more important risk for incumbent generic suppliers is additional competition, price reduction, and contract loss.

Product type	Generic entry risk	Principal barrier
Timolol maleate ophthalmic solution	Very high	Sterile manufacturing and market economics
Timolol gel-forming solution	High	Formulation development and regulatory requirements
Preservative-free timolol	High	Container systems and stability
Dorzolamide/timolol	High	Combination formulation and regulatory equivalence
Brimonidine/timolol	High	Combination formulation and market access
Novel delivery systems	Moderate	Device, formulation, and clinical development

The limiting factor is usually not patent law. It is whether expected volume supports the cost of sterile ophthalmic development, FDA approval, validation, pharmacovigilance, and commercial distribution.

Are there Paragraph IV challenges involving timolol?

Paragraph IV litigation is unlikely to create a meaningful current barrier for conventional timolol because the principal patents protecting the active ingredient and original products have expired. Paragraph IV activity is more relevant to later timolol-containing combinations, specialized formulations, and delivery systems.

Under the Hatch-Waxman framework, an ANDA applicant may certify that a listed patent is invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger litigation and a potential 30-month stay for the relevant product, subject to statutory conditions [3].

For plain timolol maleate ophthalmic solution, the commercial question is generally abbreviated approval and supply economics, not a contested patent launch. For combination products, applicants must assess each listed patent separately.

What patent litigation affects timolol?

Historical litigation involved branded ophthalmic products, generic approvals, formulations, and timolol-containing combinations. The current risk profile is limited for single-agent timolol.

The most material litigation categories are:

• ANDA litigation over combination products.
• Challenges involving gel-forming or sustained-delivery formulations.
• Disputes over formulation equivalence.
• Trademark and trade-dress disputes involving legacy brands.
• Manufacturing and supply litigation unrelated to molecule exclusivity.

There is no broad patent litigation mechanism that can restore exclusivity to the expired timolol active ingredient.

Are there licensing deals involving timolol?

Timolol has been involved in historical licensing and commercialization arrangements, particularly around the original Merck product and later fixed combinations. Current licensing value is limited for unmodified timolol because the active ingredient is off patent and widely available.

Commercial agreements may still cover:

• Regional marketing rights.
• Authorized generic supply.
• Combination-product commercialization.
• Contract manufacturing.
• Ophthalmic delivery technology.
• Preservative-free packaging systems.

A license involving a timolol-containing combination should not be treated as evidence of exclusivity for single-agent timolol.

What is the FDA regulatory status of timolol?

Timolol ophthalmic products are FDA-approved prescription drugs. FDA-approved dosage forms include solutions and gel-forming ophthalmic products. The FDA Orange Book and Drugs@FDA databases identify approved products, sponsors, application numbers, therapeutic equivalence information, and applicable patent data [2, 4].

Regulatory requirements for new generic ophthalmic timolol products include:

• Sterility assurance.
• Pharmaceutical equivalence.
• Appropriate strength and dosage form.
• Container-closure integrity.
• Stability data.
• Impurity and degradation controls.
• Manufacturing-process validation.
• Labeling consistent with the reference product.
• Demonstration of therapeutic equivalence where required.

The regulatory burden remains significant even when patent risk is minimal. Ophthalmic manufacturing failures can lead to recalls, import alerts, warning letters, or loss of customer contracts.

How strong is the timolol patent estate?

The core timolol patent estate is weak for present-day exclusivity purposes. Its commercial strength can be summarized as follows:

Patent dimension	Assessment
Active ingredient	Expired
Conventional ophthalmic solution	Expired or non-blocking
Original indication	Expired
Gel-forming formulations	Product-specific; generally limited
Fixed-dose combinations	Separate and potentially more relevant
Device and packaging claims	Narrow and product-dependent
Manufacturing process	Possible narrow barriers, but not broad market exclusivity
Biosimilar protection	Not applicable

Patent strength should therefore be assessed at the product level, not the molecule level. A company with an approved combination or specialized delivery system may retain commercial differentiation even though timolol itself is fully generic.

What is the financial trajectory for timolol?

Timolol's financial trajectory is mature, stable, and margin-constrained.

Historical phase: branded innovation

The original commercial model relied on branded ophthalmic innovation, physician adoption, and patent protection. Timoptic generated value through product differentiation and control of the first widely adopted ophthalmic beta blocker.

Genericization phase

After patent expiry, multiple generic suppliers entered. Prices declined, branded share contracted, and the product became a formulary and volume business. Combination products preserved some value because they addressed convenience and additive pressure reduction.

Current phase: portfolio and supply economics

Current revenue is distributed across many suppliers. The product is most attractive to companies with:

• Existing sterile ophthalmic capacity.
• Broad ophthalmology sales channels.
• Low-cost active pharmaceutical ingredient sourcing.
• Established hospital or government tender access.
• A portfolio of glaucoma products.
• Reliable quality systems.

Revenue growth is unlikely to come from unit expansion alone. It may come from geographic penetration, preservative-free products, combination therapy, authorized generics, and manufacturing consolidation.

What geographic markets matter most?

Timolol is sold globally, but market economics vary substantially.

United States

The U.S. market has high generic penetration and intense price competition. Product availability depends on FDA-approved manufacturing capacity and wholesaler access. Combination products and preservative-free formats may have better value than standard multidose timolol.

Europe

European markets are heavily influenced by national reimbursement, generic reference pricing, and pharmacy substitution. Timolol remains available, but country-level market share depends on tendering and reimbursement policy.

Emerging markets

Timolol can have stronger volume relevance in markets where affordability is a primary treatment determinant. Local registration, supply continuity, and government procurement often matter more than patent protection.

What manufacturing and intellectual-property barriers remain?

The main barriers are operational rather than proprietary.

Manufacturing barriers

• Sterile ophthalmic filling.
• Microbial control.
• Preservative concentration control.
• Container-closure integrity.
• Stability in multidose bottles.
• Extractables and leachables management.
• Supply continuity for bottles, droppers, and packaging components.

Intellectual-property barriers

• Narrow formulation claims.
• Combination-product patents.
• Device patents.
• Trade secrets in manufacturing processes.
• Regulatory exclusivity for a specific approved product.
• Trademark rights for legacy brands.

These barriers can protect a product niche, but they do not prevent broad generic competition with conventional timolol.

What generic launch scenarios are most likely?

Scenario 1: Conventional solution price erosion

This is the base case. Additional suppliers or manufacturing capacity reduce pricing while maintaining high unit availability. The impact is negative for incumbent suppliers but limited for patients and payers.

Scenario 2: Supply disruption and temporary price increases

Sterile ophthalmic recalls, manufacturing failures, or site closures can create short-term shortages. In that environment, suppliers with validated capacity can gain volume and improve pricing temporarily.

Scenario 3: Shift toward preservative-free products

Demand may migrate toward unit-dose or preservative-free products because of ocular-surface disease and chronic-use concerns. This could produce modest product differentiation, although the category remains exposed to generic competition.

Scenario 4: Combination-product substitution

Fixed combinations may capture value from patients requiring multiple agents. Timolol's role persists, but revenue shifts from single-agent products to dorzolamide/timolol, brimonidine/timolol, or other combination formulations.

Scenario 5: Continued clinical displacement

If prostaglandin analog access improves and clinicians prioritize once-daily treatment, timolol use may decline gradually. The decline is likely to be slow because of low cost, physician familiarity, and continued use as adjunctive therapy.

Key Takeaways

• Timolol is a mature generic ophthalmic drug with no meaningful current composition-of-matter exclusivity.
• Its main commercial forms are timolol maleate solution, gel-forming solution, and timolol-containing fixed combinations.
• Prostaglandin analogs have weakened timolol's first-line position, but the drug remains relevant because of price, availability, and adjunctive use.
• Standard timolol products face high generic-entry risk and substantial price pressure.
• The principal barriers are sterile manufacturing, quality compliance, supply continuity, and market access.
• Formulation and combination-product patents may matter at the product level, but they do not restore broad exclusivity to timolol.
• There is no biosimilar risk because timolol is a synthetic small molecule.
• Financial value is concentrated in volume, manufacturing efficiency, tenders, preservative-free delivery, and combination products.
• The most likely long-term trajectory is stable-to-declining standalone revenue with continued low-cost demand and periodic supply-driven pricing volatility.

FAQs About Timolol Market and Patent Risk

Is timolol still profitable for generic drug manufacturers?

Yes, but profitability depends on scale, sterile manufacturing efficiency, procurement contracts, and supply reliability. Standard solution margins are generally constrained by intense competition.

Can a company obtain new patents on a timolol ophthalmic product?

A company may obtain patents for a genuinely novel formulation, delivery system, combination, or manufacturing process. Such patents would be narrow and would not protect conventional timolol solution broadly.

Does timolol have 180-day generic exclusivity?

A specific ANDA applicant may receive first-filer eligibility under Hatch-Waxman rules if statutory conditions are satisfied, but any such exclusivity is product- and patent-specific. It does not create exclusivity for the timolol molecule generally.

Is preservative-free timolol commercially differentiated?

It can be differentiated through tolerability, packaging, and physician preference, but preservative-free status alone does not guarantee durable patent protection or premium pricing.

Will glaucoma treatment trends eliminate timolol demand?

No. Prostaglandin analogs will continue to pressure demand, but timolol is likely to remain in combination therapy, cost-sensitive formularies, and markets where treatment affordability and availability determine prescribing.

References

1. American Academy of Ophthalmology. (2020). Primary open-angle glaucoma preferred practice pattern. American Academy of Ophthalmology.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

3. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

DrugChatter Q&A for TIMOLOL

Timolol eye drops for migraine?
Generic timolol?